Variable | Case n = 675 | Control n = 2025 | Odds ratio [95% CI] | P value |
---|---|---|---|---|
Sex, male | 400 (68.1) | 1,380 (68.1) | Matched | Â |
Age, years | 57.8 ± 10.4 | 57.8 ± 10.4 | Matched |  |
Insurance type | Â | Â | Matched | Â |
Health insurance | 668 (99.0) | 2004 (99.0) | Â | Â |
Medical aid | 7 (1.0) | 21 (1.0) | Â | Â |
Comorbidities | ||||
 Hypertension | 352 (52.1) | 1056 (52.1) | Matched |  |
 Renal disease | 39 (5.8) | 117 (5.8) | Matched |  |
Medication | ||||
 Antiplatelet | 261 (38.7) | 789 (38.7) | Matched |  |
 RAAS inhibitor | 302 (44.7) | 906 (44.7) | Matched |  |
 Statin | 219 (32.4) | 778 (38.4) | 0.73 [0.59–0.89] | 0.002 |
Cumulative statin exposure | ||||
  < 1 year | 431 (63.9) | 1129 (55.8) | 1 (Ref) |  |
 1–3 year(s) | 103 (15.3) | 352 (17.4) | 0.73 [0.57–0.94] | 0.015 |
  > 3 years | 141 (20.9) | 544 (26.9) | 0.60 [0.47–0.77] |  < 0.001 |